Garo Hagopian
Overview
Explore the profile of Garo Hagopian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagopian G, Yazdanpanah O, Tran M, Lee L
BMJ Case Rep
. 2024 Aug;
17(8).
PMID: 39179258
A woman in her 40s with no medical history presented on hospital day #0 with 3 days of epigastric pain, nausea, vomiting and bloody diarrhoea. Initial blood work demonstrated acute...
2.
Yeakel J, Seyedin S, Harada G, Hagopian G, Mahmood S, Bennett R, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001464
Y-90 Selective Internal Radiotherapy (SIRT) is an ablative therapy used for inoperable liver metastasis. The purpose of this investigation was to examine the impact of local control after SIRT on...
3.
Hagopian G, Grant C, Lou J, Johnson C, Pakbaz Z
J Community Hosp Intern Med Perspect
. 2024 Apr;
13(6):13-16.
PMID: 38596563
We present the case of a 64-year-old female who was referred by her oncologist to benign hematology clinic for persistent asymptomatic cryoglobulinemia. Workup led to diagnosis of a rare low...
4.
Grant C, Hagopian G, Ponce-Zepeda J, Chandan V, Pakbaz Z
J Community Hosp Intern Med Perspect
. 2024 Apr;
13(6):29-34.
PMID: 38596560
We present here a 66-year-old Caucasian male whose persistent abdominal pain thought to be due to appendicitis and associated acute splanchnic thrombosis. He was initially managed with antibiotics and anticoagulation....
5.
Hagopian G, Nagasaka M
Crit Rev Oncol Hematol
. 2023 Dec;
194:104234.
PMID: 38122917
Non-Small Cell Lung Cancer (NSCLC) is responsible for the highest number of cancer-related deaths in the United States. Thankfully, advancements in the detection and targeting of gene mutations have greatly...
6.
Lopez M, Hagopian G, Doan L, Lee B, Rojek N, Smith J, et al.
Allergy Asthma Clin Immunol
. 2023 Oct;
19(1):93.
PMID: 37898814
Background: Osimertinib has emerged as an important tool in the treatment of non-small cell lung cancers (NSCLC) with certain activating mutations of epidermal growth factor receptor (EGFR). However, Osimertinib may...
7.
Grant C, Hagopian G, Nagasaka M
Crit Rev Oncol Hematol
. 2023 Aug;
190:104080.
PMID: 37532102
Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment...
8.
Hagopian G, Grant C, Nagasaka M
Cancer Treat Rev
. 2023 May;
117:102561.
PMID: 37178629
Non-small cell lung cancer (NSCLC) has very poor prognosis in advanced stages. Discovery and application of therapies targeting specific oncogenic driver mutations has greatly improved overall survival. However, targeted therapies...
9.
Grant C, Hagopian G, Tran T, Nagaraj G, Moyers J
J Immunother Cancer
. 2023 Jan;
10(12).
PMID: 36600605
No abstract available.
10.
Kaakour D, Hagopian G, Lee S, Lee F
Am J Clin Oncol
. 2022 Sep;
45(10):410-414.
PMID: 36102355
Objectives: Biliary tract tumors have a poor prognosis despite advancements in targeted therapies. More recent studies have started to investigate the use of combination immunotherapy in advanced biliary cancers. However,...